Evidence map›Paper›PMID 26303027›Full record

ArticleLipids in health and disease2015

A comparative study between Wuweizi seed and its post-ethanol extraction residue in normal and hypercholesterolemic mice.

Zhu-Sheng Chu, Zhi-Ling Yu, Si-Yuan Pan, Zhan-Hong Jia, Xiao-Yan Wang, Yi Zhang, Pei-Li Zhu, Xiu-Juan Wang, Kam-Ming Ko

Open access · goldAbstract readComparative Study
In one paragraph

Article in Lipids in health and disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Zhu-Sheng ChuSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100102, China. chuzhusheng@vip.qq.com.
Zhi-Ling YuSchool of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China. zlyu@hkbu.edu.hk.
Si-Yuan PanSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100102, China. siyuan-pan@163.com.
Zhan-Hong JiaSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100102, China. awmt_2004@163.com.
Xiao-Yan WangSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100102, China. wangxiaoyan1083@126.com.
Yi ZhangSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100102, China. wozhenaimeizhi@sina.com.
Pei-Li ZhuSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100102, China. pellyzhu@126.com.
Xiu-Juan WangSchool of Traditional Medicine, Capital Medical University, Beijing, 100069, China. wxj0517@sina.com.
Kam-Ming KoDivision of Life Science, Hong Kong University of Science & Technology, Hong Kong, China. bcrko@ust.hk.
Beijing University of Chinese Medicine · CNCapital Medical University · CNHong Kong Baptist University · HKHong Kong University of Science and Technology · HK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAt the present, a shift from drug therapy, especially herbal therapy, to dietary supplementation is a trend in the management of dyslipidemia and related diseases. Therefore, the optimal utilization of herbal resource is important for a sustainable development of herbal medicine. Here, we compared the effects of dietary supplementation with Chinese medicine Schisandrae Chinensis Fructus seed (FSC-S) and the post-ethanol extraction residue of FSC-S (FSC-SpEt) on normal diet-fed (normal) and experimental hypercholesterolemic (HCL) mice.

methodsMale ICR mice (n = 10 in each group), weighing 17-21 g, were fed with normal diet (ND) or high cholesterol/bile salt (1/0.3 %, w/w) diet (HCBD) with or without supplemented with FSC-S, FSC-SpEt), or lipid-lowering agent fenofibrate (FF). Ten days later, serum/hepatic lipid and glucose (GLU) levels, body weight, organ/epididymal fat masses, and food/water intake were measured. Lipid level measurements included those of total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL), HDL/LDL ratio, LDL/HDL ratio, and non-HDL (N-HDL).

resultsSupplementation with FSC-S and FSC-SpEt increased serum TC (by 64 and 25 %, respectively) and LDL (by 60 and 27 %, respectively) in normal mice. FSC-S supplementation elevated serum TC, TG, HDL, LDL, and LDL/HDL ratio (up to 64, 118, 77, 197, and 51 %, respectively) in HCL mice. FSC-SpEt supplementation reduced serum TG (by 15 %) and LDL/HDL ratio (by 18 %), as well as increased serum HDL (by 22 %) and HDL/LDL ratio (by 21 %) in HCBD-fed mice. FSC-S decreased hepatic TC (by 19 %) contents and increased hepatic TG contents by 14 % in normal mice. FSC-S reduced hepatic GLU level in both normal and HCL mice by 24 and 22 %, respectively. Hepatic TC and TG contents were lowered in FSC-SpEt-supplemented normal mice by 16 and 20 %, respectively. The body/fatty masse and food intake were lowered, but the feed efficiency index (FEI), weight gain per unit of food ingested, was increased in FSC-S-supplemented normal and HCL mice. FF supplements reduced serum/hepatic lipids, hepatic GLU contents, and epididymal fat mass, but it induced hepatomegaly and high serum alanine aminotransferase (ALT) activity in normal and/or HCL mice.

conclusionThe ensemble of results indicated that while FSC-SpEt supplementation is beneficial for the treatment of hyperlipidemia/fatty liver, FSC-S is potentially useful for the management of overweight/obesity.

Indexed as

Adipose TissueAnimalsAnticholesteremic AgentsBlood GlucoseBody WeightCholesterol, DietaryCholesterol, HDLCholesterol, LDLDiet, High-FatDrinkingEatingEthanolFatty LiverFenofibrateHypercholesterolemiaLiverAnticholesteremic AgentsBlood GlucoseCholesterol, DietaryCholesterol, HDLCholesterol, LDLEthanolFenofibratePlant ExtractsSolventsTriglycerides

Identifiers

PMID26303027
PMCPMC4549086
OpenAlexW2154555646

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.